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Summary
Background.— Ajmaline challenge is commonly used for the diagnosis of Brugada syndrome. A
slow infusion rate has been recommended in view of the proarrhythmic risk, but the diagnostic
value of various infusion rates has not been investigated.
Aims.— To compare rapid and slow ajmaline infusion rates and to assess the proarrhythmic risk.
Methods.— The ﬁrst part of this study prospectively compared rapid and slow infusion rates
in terms of results and ventricular arrhythmias. Thirty-two patients (mean age 41± 12 years;
26 men) received the two ajmaline challenges on different days. According to randomization,
ajmaline (1mg/kg) was infused at 1mg/sec or over 10minutes. The second part of the study ret-
rospectively assessed the prevalence of ventricular arrhythmia during 386 challenges performed
at a rapid infusion rate.
Results.— No differences were observed between rapid and slow tests. All patients diagnosed
as positive or negative with one test obtained the same result with the other test. Ventricular
premature beats were observed in ﬁve of 32 patients during the slow challenge and in four of 32
patients during the rapid challenge. No sustained ventricular arrhythmias were observed. Anal-
ysis of the 386 tests revealed four episodes of ventricular arrhythmia (two complex ventricular
premature beats, one non-sustained ventricular tachycardia and one ventricular ﬁbrillation).
Abbreviations: BS, Brugada syndrome; ECG, electrocardiogram; NSVT, non-sustained ventricular tachycardia; VA, ventricular
arrhythmia; VF, ventricular ﬁbrillation; VPB, ventricular premature beat; VT, ventricular tachycardia.
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performances diagnostiques dans les suspicions d’ECG de Brugada. En raison du risque
d’arythmie ventriculaire sévère, une administration plus lente, permettant l’arrêt précoce de
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Background
BS is associated with a risk of sudden death due to VF
[1]. ECG abnormalities include J point elevation by at
least 0.2mV and a coved pattern of the ST segment with
a negative T wave in the right precordial leads. Right
bundle branch block can also be associated with the syn-
drome [2]. These signs are sometimes intermittent. In
1996, Miyasaki et al. showed that ST elevation can be
revealed by the use of sodium channel blocking agents
[3]. Ajmaline and ﬂecainide have been used in Europe,
procainamide in the USA and pilsicainide in Japan. The
various drugs have been compared, and ajmaline has the
highest sensitivity for detection of BS [4]. However, ajma-
line may have proarrhythmic effects and different infusion
rates have been recommended [2,5—8]. Administration of
1mg/kg at the rate of 10mg/min was proposed at the ﬁrst
consensus conference [2]. Ajmaline challenge stopping cri-
teria were deﬁned in 2003 in order to avoid proarrhythmic
effects. Fractionated administration of a dose of 10mg every
2minutes to reach a total dose of 1mg/kg was proposed
[8]. In 2005, the second consensus conference recommended
a dose of 1mg/kg over 5minutes [9]. Other teams have
reported their experience with protocols used to study
conduction disorders, i.e. 1mg/kg at a rate of 1mg/sec
[10,11]. Finally, other authors (such as Wolpert et al.) use
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mg/kg over 10minutes [4]. No randomized study has com-
ared the sensitivity/speciﬁcity and risks associated with
he various ajmaline administration protocols. Ajmaline
nduces concentration-dependent, frequency-independent
nd voltage-dependent sodium channel blockade [12], and
oncentration-dependent and frequency-independent inhi-
ition of the transient outward potassium current [13]. The
ate of administration of ajmaline, by modifying the peak
lasma concentration, can alter potassium channel inacti-
ation and reactivation kinetics and modulate the intensity
nd duration of sodium channel blockade. Furthermore, as
he time to onset of action of ajmaline is 2 to 3minutes,
apid injection of ajmaline (1mg/sec for a dose of 1mg/kg)
nduces higher cardiac concentrations than the same dose
njected over 10minutes. Rapid injection could accentuate
point elevation during the ﬁrst minutes to the detriment
f the speciﬁcity of the test. Inversely, the dose injected
ver 10minutes could reduce the sensitivity of the test. The
bjective of this study was to compare the electrocardio-
raphic effects of two rates of administration of ajmaline
nd to determine whether the diagnostic contribution is
odiﬁed by the ajmaline administration rate. Retrospec-
ive evaluation of the prevalence of VA in a series of 386sis of Brugada syndrome: Which protocol? 571
Conclusion.— Slow and rapid infusions of ajmaline have identical diagnostic performances on
suspected Brugada electrocardiograms. Owing to the risk of severe proarrhythmia, a slow infu-
sion rate, allowing early discontinuation, should be recommended.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Background.— Le test à l’ajmaline est couramment utilisé pour le diagnostic du syndrome
de Brugada. Une administration lente de l’ajmaline est recommandée en raison du risque
d’arythmie, mais sa valeur diagnostique n’a pas été évaluée.
Objectifs.— Comparer la valeur diagnostique des vitesses rapide et lente d’administration de
l’ajmaline et évaluer le risque proarythmogène.
Méthodes.— La première partie de l’étude a consisté à comparer de fac¸on prospective les
résultats et le taux de survenue d’arythmie ventriculaire pour deux vitesses d’administration
de l’ajmaline. Trente-deux patients (hommes = 26; moyenne d’âge 41± 12 ans) ont réalisé deux
tests à l’ajmaline sur deux jours distincts. Selon la randomisation, l’ajmaline (1mg/kg) a été
administrée à la vitesse d’1mg/s ou sur dixminutes. La seconde partie de l’étude a évalué
de fac¸on rétrospective la prévalence des arythmies ventriculaires de 386 tests réalisés avec un
protocole rapide d’administration de l’ajmaline.
Résultats.— Aucune différence n’a été observée entre le test rapid et le test long. Tous
les patients ayant un test rapide positif (15/32 [47 %]), ont eu également un résultat posi-
tif pour le test long. Des extrasystoles ventriculaires isolées ont été observées chez cinq sur
32 patients durant le test long et chez quatre sur 32 patients lors du test rapide. Aucun épisode
d’arythmie ventriculaire soutenue n’est survenu. L’analyse des 386 tests rapides a mis en évi-
dence quatre épisodes d’arythmie ventriculaire (deux extrasystoles ventriculaires complexes,
une tachycardie ventriculaire non soutenue, une ﬁbrillation ventriculaire).
Conclusion.— Les protocoles rapide et lent d’administration de l’ajmaline offrent les mêmesests performed with injection of 1mg/sec was designed
o estimate the proarrhythmic risk during rapid injection of
jmaline.
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ethods
atients
he study was approved by the local ethics committee.
ach subject signed an informed consent form. Between
005 and 2008, 32 consecutive subjects with type 2 or 3 BS
ere prospectively included in the ﬁrst phase of the study.
n this population, ECG changes were disclosed after the
nset of symptoms, incidentally or in the context of fam-
ly screening. Exclusion criteria were contraindications to
jmaline (previous myocardial infarction, heart failure or
mpaired left ventricular ejection fraction, complete left
undle branch block, bifascicular block, second- or third-
egree atrioventricular block, use of a class I antiarrhythmic
gent, pregnancy or breastfeeding, children under the age
f 15 years).
The second phase of the study consisted of retrospec-
ive evaluation of ajmaline challenges performed with the
apid injection protocol between January 2002 and July
009. This phase comprised 386 subjects in whom the test
as performed for family screening of BS or sudden death,
nexplained syncope, discovery of type 2 or 3 ECG, or
esuscitated cardiac arrest. ECG recordings were reviewed
peciﬁcally for the analysis of VAs. Single VPBs, complex
PBs (frequent VPBs, polymorphic VPBs, bigeminy, cou-
lets), NSVT and VF were notiﬁed.
jmaline challenges
jmaline challenges were conducted in the electrophysi-
logy laboratory, in the presence of a cardiologist. Each
atient underwent two ajmaline challenges, and the order
as determined by randomization, with a crossover design.
he two tests were performed on different days, < 1 month
part. All tests were performed at the same time of the
ay, in the late morning. Tests were preceded by echocar-
iography and -human chorionic gonadotropin if necessary.
he ajmaline injection was performed at a dose of 1mg/kg,
ither at an infusion rate of 1mg/sec or over 10minutes.
Continuous 12-lead ECG monitoring, including leads V1
nd V2 in the second intercostal space, was performed on
computerized electrophysiology system (EP Med Systems,
J, USA). Measurements were performed with the software
allipers, at a time-scale of 200mm/sec at T0 (0minutes),
3 (T0 + 3minutes), T5 (T0 + 5minutes) and T10 (T0 +
0minutes) after the end of injection for the two proto-
ols, and at T0, T3 and T5 after the beginning of injection
or the slow test. ECGs were printed on paper at these dif-
erent times and recorded continuously on optical disk. The
resence of any arrhythmias was recorded. At the end of
dministration of ajmaline, the ECG recording continued
ntil the reading returned to normal. The test results were
valuated by two independent, blinded observers. The test
as considered positive if more than one lead exhibited
oved type with a J point elevation > 0.2mV [2].tatistics
ariables are expressed as means and standard deviations.
omparisons between groups were performed by analysis of
ariance or by using the Wilcoxon test for paired samples.
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paired Student’s t test was used to compare paired vari-
bles. Tests were considered to be signiﬁcant for p < 0.05.
tatistical analysis was performed with SPSS software Ver-
ion 11 (SPSS Inc., Chicago, IL, USA).
esults
art I
tudy population
ubjects had a mean age of 40.9± 12 years (range 19—69);
he sex ratio was 4.3 (81.2% men). Patients had a type 2 ECG
n 22 (68.8%) cases and a type 3 ECG in 10 (31.2%) cases.
ymptoms consisted of syncope (n = 5), faintness (n = 2) or
alpitations (n = 11). The other subjects were asymptomatic
n = 14) and their ECG abnormality was found during a family
creening (n = 7) or fortuitously (n = 7).
est results
he concordance between rapid tests and slow tests was
00%. All patients diagnosed as positive or negative with one
est obtained the same result with the other test. No dif-
erence in the results was observed between the two tests
ccording to readings by the two observers (Fig. 1). The
ositive ajmaline challenge rate was 46.9% (15/32). Ajma-
ine challenges were more often positive for type 2 ECGs
han for type 3 ECGs (p < 0.001). No signiﬁcant difference in
he VPB rate was observed according to the protocol used
p = 0.51). VPBs occurred in three subjects during positive
ests and in ﬁve subjects during negative tests. No runs of
PBs were observed during the 64 tests; ECG changes were
dentical for the two protocols (Table 1) and for both positive
nd negative tests, except for the QTc interval (Table 2). The
aximum variation of the amplitude of J point was observed
n lead V2 for the two tests, in 75 and 69% of cases, respec-
ively. The peak changes in J point elevation, PR, RR, QRS
nd QTc interval were observed 3minutes after injection,
xcept in RR in the slow test (Figs. 2 and 3).
art II
tudy population
ubjects had a mean age of 42± 15 years (range 15—81);
5% were men. Tests were performed for family screening
n 290 (75%) cases. Sixteen (4.2%) patients had a history of
yncope and two (0.6%) had a history of resuscitated sudden
eath. Fifty-ﬁve (14%) patients had a family history of sud-
en death. The ECG was normal in 264 (68%) cases, transient
ype 1 in 38 (10%) cases and type 2 or 3 in 84 (22%) cases.
esults and complications of ajmaline challenge
he ajmaline challenge was positive in 183 (47%) patients.
wo (0.5%) of the 386 patients presented runs of monomor-
hic VT (a triplet of VPBs and a triplet of VPBs followed
y a doublet), with no recurrence during subsequent ECG
onitoring. Another two (0.5%) patients presented serious
As. The ﬁrst patient, a 29-year-old woman, presented poly-
orphic NSVT of 15 complexes over 7 s, occurring 1minute
fter the onset of a type 1 appearance on the ECG, i.e.
minutes after the end of the injection of the entire dose
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Table 1 ECG variables: rapid vs slow infusion.
Variable Rapid infusion (n = 32) Slow infusion (n = 32) pa
Baseline 3 minutes  (%) Baseline 10 minutes  (%)
PR (ms) 167 ± 28 219 ± 3 6 32.5 166 ± 32 217 ± 33 32.8 0.8
QRS (ms) 103 ± 14 134 ± 18 31.7 100 ± 13 132 ± 17 33.6 0.8
QTc (ms) 425 ± 37 481 ± 32 13.7 403 ± 24 470 ± 39 16.7 0.2
RR (ms) 847 ± 78 740 ± 10 —11.1 902 ± 133 754 ± 87 —15.5 0.06
J wave (mV) 0.28 ± 0.1 0.51 ± 0.17 95.0 0.26 ± 0.1 0.51 ± 0.22 96.8 0.5
a Comparison between infusion protocols.
Table 2 ECG variables: positive vs negative test.
Variable Infusion rate Positive test (n = 15) Negative test (n = 17) p
ms % ms %
PR Rapid 58 ± 31 36.4 48 ± 24 29.1 0.3
Slow 48 ± 20 29.2 54 ± 29 36.0 0.3
QRS Rapid 34 ± 16 34.2 29 ± 15 29.5 0.3
Slow 33 ± 18 33.9 32 ± 14 33.3 0.8
QTc Rapid 69 ± 37 16.9 45 ± 28 10.9 0.05
Slow 70 ± 42 17.1 64 ± 31 16.4 0.4
—12.
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Slow —125 ± 72
of ajmaline. Widening of the QRS and J point elevation was
observed before the run (Fig. 4). The test was performed in
the context of BS screening in a family of 15 cases of BS. The
ECG before the test was normal. The second case occurred
in an asymptomatic 21-year-old woman also consulting in
the context of family screening. The ECG before the test
was normal. Three minutes after the end of the injection,
a type 1 ECG pattern on lead V1 was observed, with widen-
ing of the QRS > 130%, followed by VF. Sinus rhythm was
restored after 30minutes of resuscitation, without neurolog-
ical repercussion (Fig. 5). Resuscitation included repeated
electrical shocks, infusion of sodium bicarbonate, a bolus of
adrenaline and isoproterenol. Intravenous isoproterenol was
administered as a continuous infusion of 0.06mg/min for
15minutes, and stopped a few minutes after sinus rhythm,
without recurrence of ventricular event. A Scarpa surgical
approach was done in preparation for circulatory support,
but was not necessary due to return to sinus rhythm. An
implantable cardioverter deﬁbrillator was inserted a few
days later. Genetic analysis subsequently revealed an SCN5A
gene mutation (G1743R).
Discussion
No signiﬁcant difference was observed between the slow
test and the rapid test in terms of diagnostic performance,
variation in ECG variables or the frequency of isolated VPBs.
The development of isolated VPBs was not correlated with a
positive ajmaline challenge. In contrast, runs of polymorphic
VT were preceded by ECG changes typical of BS. The risk of
t
o
n
t
a2 —94 ± 86 —10.1 0.5
4 —167 ± 124 —17.3 0.2
otentially fatal arrhythmias was 0.5% during the rapid test.
No studies evaluating the diagnostic performances of the
jmaline challenge as a function of injection rates in BS have
een published in the literature. Independently of injection
ate, the lengthening of QRS, PR and QTc intervals observed
n this study was identical to that observed in previous stud-
es [14,15], including in studies performed in BS patients
5,8,16]. All ajmaline tests were performed at the same time
f the day to avoid spontaneous nycthemeral ECG ﬂuctua-
ions [17].
In the studies by Batchvarov et al. [5] and Veltmann et al.
16], only lengthening of the QTc interval (but not heart rate,
R interval or QRS width) was slightly greater on positive
ests. These data are in line with those reported with the
apid test in the ﬁrst part of this study and conﬁrm the good
CG tolerance of this protocol.
Literature reports of the risk of VA during sodium chan-
el blockade challenge in BS are summarized in Table 3.
tudies in which the presence of type 1 ECG was most fre-
uent reported the highest rates of proarrhythmias. This
ppears to be true regardless of the type of sodium chan-
el blocking agent used. However, it should be noted that
risk of VF was also observed when the ECG was strictly
ormal before the injection (Fig. 5), and when the injec-
ion was performed over 5minutes [16]. In view of the risk
f fatal arrhythmias, as recommended by Rolf et al. [8],
he injection of ajmaline should therefore be performed
ver 10minutes and should be stopped in the case of sig-
iﬁcant J point elevation or widening of the QRS by more
han 130%. Ajmaline has the advantage of a shorter half-life
nd a briefer blocking effect on transient outward potassium
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Table 3 Ventricular arrhythmias during sodium channel blockade challenge.
Study
reference
Drug used N Type 1ECG (%) SCD or
syncope (%)
Testpositivity (%) VPB (%) VA (%)
Brugada
et al., 2000
[18]
Ajmaline 5
min
Flecainide
Procainamide
106 32 > 32 42 Frequent
VPBs: 4.7
VF: 1.3
with
ajmaline
Rolf et al.,
2003 [8]
Ajmaline 10
mg/2 min
158 3.8 SCD: 13.3
Syncope:
60.1
23.4 Not
reported
VT: 1.3 but
0 after
protocol
change
Gasparini
et al., 2003
[19]
Flecainide 22(41 tests) 86.4 SCD: 9.1
Syncope:
36.4
100 Not
reported
VT: 7.3
VF: 2.5
Morita
et al., 2003
[24]
Pilsicainide 65 100 15.4 100 Frequent
VPBs: 9.2
VT: 6.2
Meregalli,
2006 [20]
Flecainide 160 No SCD: 10.6
Syncope:
18.1
40 Single
VPBs: 6
Frequent
VPBs: 0.6
0
Chinushi
et al., 2007
[21]
Pilsicainide 28 64.3 SCD: 10.7
Syncope:
42.9
100 Frequent
VPBs: 7.1
VT: 11
Batchvarov
et al., 2009
[5]
Ajmaline 5
min
148 No SCD: 12.8
Syncope:
27.0
20.3 Single
VPBs: 8.1
Complex
VPBs: 4.7
NSTV: 2
Veltmann
et al., 2009
[16]
Ajmaline 5
min
677 No SCD: 1.8
Syncope:
25.7
39 VPB: 1.2 NSTVL 0.30
VF: 0.15
Our study,
part II
Ajmaline 1
mg/sec
386 9.8 SCD: 0.6
Syncope:
4.2
47.3 Single
VPBs: 14.1
Complex
VPBs: 0.26
NSTV: 0.8
VF: 0.26
ECG: electrocardiogram; NSVT: non-sustained ventricular tachycardia; SCD: sudden cardiac death; VA: ventricular arrhythmia; VF: ventricular ﬁbrillation; VPB: ventricular premature
beat; VT: ventricular tachycardia.
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Figure 1. Bland and Altman plots of J wave amplitude (JWA)
changes with the two infusion protocols, at 0minutes (T0),
3minutes (T3) and 5minutes (T5) after the end of injection. The
mean of J point elevation is represented by the abscissa (x-axis)
value, and the difference between J point elevation by the ordi-
nate (y-axis) value. The graph showed good agreement between
the two protocols.
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bigure 2. Kinetics of J point amplitude during slow and rapid
ests, at 0minutes (T0), 3minutes (T3), 5minutes (T5) and
0minutes (T10) after the end of injection (means± standard devi-
tions).
urrent than other sodium channel blocking agents, and is
herefore more rapidly reversible [13,22]. Predictive factors
or the development of arrhythmia during sodium channel
lockade challenge performed for the detection of BS are
ifﬁcult to deﬁne because of the rarity of these events.
ccording to Chinushi et al., the frequency of VPBs is higher
n the presence of marked ST elevation before the test,
ut identical whether or not patients are symptomatic [21].
atchvarov et al. emphasized the higher incidence of VAs
uring positive tests compared with negative tests [5], sug-
esting that the test should be stopped as soon as a positive
esponse is observed.
In our study, the two cases of severe polymorphic arrhyth-
ia occurred in female patients with no personal or family
istory of sudden death and with a strictly normal base-
ine ECG. The risk of arrhythmia was assumed to be low.
G1743R mutation was demonstrated in one patient. This
utation, responsible for a marked reduction of the density
f sodium current channels, has been previously reported
y Valdivia et al. [23]. The other patient was not screened
or SCN5A mutations. In view of the different morphology
f the VPBs, Morita et al. [24] also proposed a different
rigin of the arrhythmia between subjects with or with-
ut SCN5A mutations, which could therefore explain the
ncreased proarrhythmic risk in patients presenting such a
utation. A high rate of VA (43%) was reported during ﬂe-
ainide challenge in the presence of an SCN5A mutation in
he studies by Gasparini et al. [19]. The presence of an
CN5A mutation may therefore be predictive of the devel-
pment of proarrythmia.
Isoprenaline efﬁciency had been described in the con-
ext of electrical storm in patients with BS [25—28], and
n cases of VA induced by drugs such as procainamide and
ilsicainide [29,30]. It also seems to be effective in VA gen-
rated by ajmaline. Isoproterenol is known to restore the
ome of epicardial action potential and to normalize the ST
egment by increasing the inward calcium current [31]. Its
eta-adrenergic stimulation has been added in our clinical
576 E. Arnalsteen-Dassonvalle et al.
Figure 3. Kinetics of PR, QRS, QTc and RR intervals during slow and rapid tests, at 0minutes (T0), 3minutes (T3) and 5minutes (T5) after
the end of injection (means± standard deviations).
Figure 4. Development of polymorphic non-sustained ventricular tachycardia at the third minute of a rapid ajmaline challenge.
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Figure 5. Development of ventricular ﬁbrillation 3minutes after rapid intravenous administration of 60mg of ajmaline in a 20-year-old
woman. Panel A: 12-lead electrocardiogram before the test; no ST elevation in the right precordial leads. Panels B and C: progressive
increase in the QRS duration and appearance of features of right bundle branch block with J point elevation (type 1 pattern) on lead
vent
effe
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RV1. Panel D: polymorphic ventricular tachycardia then intractable
intravenous administration of isoproterenol. Panel E: restoration of
case to an increased sympathetic activity due to adrenaline
injection. The isoproterenol concentrations that we used
(0.06mg/min) were larger than those usually described in
the electrical storms (0.1 to 1g/min) [25,26,28,30,32]. The
irreducible character of VF, despite electrical shocks, jus-
tiﬁes this high dose. Ablation of the triggering ventricular
ectopies has been described in electrical storms in case of
failure of therapeutic options [33]. Our therapeutic option
was cardiopulmonary ‘‘bypass’’ because of the emergency.
Heart transplantation has already been described as a last
resort [34].
One limitation is related to the power of the ﬁrst part
of our study. After a post-hoc calculation, a cohort of at
least 80 patients would have been necessary to prove with
a probability of 80% the absence of difference between the
two tests.
Clinical implications
The analysis of 386 ajmaline challenge tests showed that
rapid administration of ajmaline is associated with a risk
of severe VA, even in asymptomatic patients with normal
baseline ECG. The sensitivity of the test was not decreased
by slowing the rate of administration of ajmaline over
10minutes. The 10-minute ajmaline challenge is therefore
recommended.ricular ﬁbrillation for 30minutes despite 10 electrical shocks and
ctive sinus rhythm after the 11th shock.
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